Skip to content

A randomized controlled trial of yeast beta-glucan on cognitive function in patients with mild cognitive impairment

Effect and mechanism of yeast ß-glucan on cognitive function in patients with mild cognitive impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072848
Enrollment
Unknown
Registered
2023-06-27
Start date
2023-06-27
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment

Interventions

Intervention group:Take yeast beta-glucan capsules 250mg/ capsule daily, 2 capsules in the morning and night
Placebo group:Take starch capsules 250mg/ capsule every day, 2 capsules in the morning and evening

Sponsors

Shiyan City, Hubei Province, Hubei Medical College affiliated Sinopharm Dongfeng General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) 50-80 years old; (2) Permanent residents of Shiyan City; (3) Meet the diagnostic criteria of MCI; (4) Willing to cooperate in completing questionnaire survey and clinical examination, and sign informed consent; (5) Did not participate in other clinical trials in the past 3 months. The diagnostic criteria for MCI are as follows: (1) The subjective feeling of memory loss > 3 months; (2) Objective examination of mild cognitive dysfunction, 18 points = MoCA score = 25 points (education years less than 6 years, the total score added 1 point to evaluate); (3) No depression, GDS-30 scale =10 points; (4) The basic activities of daily living were normal, but the instrumental activities of daily living (ADL) score scale =18 points; (5) had not reached the diagnostic criteria for dementia, and the CDR scale score was equal to 0.5 points.

Exclusion criteria

Exclusion criteria: (1) alcohol or drug abuse; (2) Patients with neurological diseases that may cause cognitive dysfunction, including cerebrovascular diseases, stroke, brain tumors, Parkinson's disease, active epilepsy, etc.; (3) A history of severe head trauma; (4) severe sensory and perceptual impairment, unable to complete the cognitive function measurement; (5) Have a history of mental illness such as depression, mania, anxiety, or take psychiatric drugs; (6) serious heart, lung, liver, kidney dysfunction, malignant tumors, etc.; (7) Suffering from autoimmune diseases; (8) Trauma, spinal injury or any disease that may affect the motor function of the limb; (9) Recent infectious diseases, acute gastrointestinal diseases; (10) Take antibiotics, probiotics, prebiotics or Biostime products within the last 1 month.

Design outcomes

Primary

MeasureTime frame
MoCA score;

Secondary

MeasureTime frame
Cognitive function tests in different areas;Detection of lymphocyte subsets(YNMT)· ;Plasma inflammatory factor;

Countries

China

Contacts

Public ContactXiulou Li

Sinopod Dongfeng General Hospital, 16 Daling Road, Zhangwan District, Shiyan City, Hubei Province

921187179@qq.com+86 138 7278 0830

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026